Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate

Yang-Ming Zhang,Hai-Yan Xu,Hai-Ning Hu,Fu-Yun Tian,Fei Chen,Hua-Nan Liu,Li Zhan,Xiao-Ping Pi,Jie Liu,Zhao-Bing Gao,Fa-Jun Nan

DOI: https://doi.org/10.1021/acs.jmedchem.0c02252

IF: 8.039

2021-04-30

Journal of Medicinal Chemistry

Abstract:We previously reported that P-retigabine (P-RTG), a retigabine (RTG) analogue bearing a propargyl group at the nitrogen atom in the linker of RTG, displayed moderate anticonvulsant efficacy. Recently, our further efforts led to the discovery of HN37 (pynegabine), which demonstrated satisfactory chemical stability upon deleting the ortho liable −NH2 group and installing two adjacent methyl groups to the carbamate motif. HN37 exhibited enhanced activation potency toward neuronal Kv7 channels and high in vivo efficacy in a range of pre-clinical seizure models, including the maximal electroshock test and a 6 Hz model of pharmacoresistant limbic seizures. With its improved chemical stability, strong efficacy, and better safety margin, HN37 has progressed to clinical trial in China for epilepsy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02252?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02252</a>.Additional information for the CYP inhibition study and TDI assessment, time effect of HN37 in the mouse MES test, quantitative anticonvulsant effects of HN37 and RTG in rat MES test, and NMR and HPLC spectra for final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02252/suppl_file/jm0c02252_si_001.pdf">PDF</a>)Molecular formula strings for all the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02252/suppl_file/jm0c02252_si_002.csv">CSV</a>).This article has not yet been cited by other publications.

chemistry, medicinal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a new, chemically stable and highly effective anti - epilepsy drug candidate. Specifically, the research aims to improve the chemical stability and efficacy of existing anti - epilepsy drugs (such as retigabine) through structural modification while reducing their side effects. ### Main Problems and Background 1. **Problems of Existing Drugs**: - **Retigabine (RTG)** is a drug approved for the treatment of partial - onset epilepsy, but it has some significant side effects, such as dizziness, fatigue, and vision problems. - The chemical structure of RTG is prone to cause pigmentation, especially after long - term use, which may lead to discoloration problems in the skin and eyes. - The polyaminobenzene structure of RTG makes it easy to form colored dimers in an oxidative environment, affecting its stability. 2. **Improvement Goals**: - **Enhance Chemical Stability**: By removing reactive functional groups (such as ortho - NH₂) and introducing other groups (such as methyl), the chemical stability of the compound is enhanced. - **Enhance Efficacy**: Ensure that the new compound maintains or improves the anti - epilepsy effect while reducing side effects. - **Improve Pharmacokinetic Properties**: Optimize the brain - blood distribution ratio of the compound to improve efficacy and reduce adverse reactions. ### Research Results After a series of structural modifications and activity tests, the researchers finally discovered the compound **HN37 (pynegabine)**, which has the following advantages: - **Chemical Stability**: By removing the ortho - NH₂ group and introducing two adjacent methyl groups, HN37 shows good chemical stability. - **High Efficiency**: HN37 shows a higher ability to activate neuronal Kv7 channels in multiple epilepsy models and exhibits a stronger anti - epilepsy effect than RTG in in - vivo experiments. - **Safety**: HN37 has a better safety margin and reduces the risk of side effects. Therefore, as a new anti - epilepsy drug candidate, HN37 has entered the clinical trial stage in China, providing a new option for epilepsy treatment. ### Summary This paper successfully solves the problems of chemical instability and side effects of existing anti - epilepsy drugs through systematic structural optimization and activity evaluation, and discovers a new drug candidate HN37 with potential clinical application value.

Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate

Identification of a New Retigabine Derivative with Improved Photostability for Selective Activation of Neuronal Kv7 Channels and Antiseizure Activity.

Discovery of 7-alkyloxy- [1,2,4] triazolo[1,5-a] pyrimidine derivatives as selective positive modulators of GABAA1 and GABAA4 receptors with potent antiepileptic activity

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

Design, synthesis, biological evaluation, homology modeling and docking studies of (E)-3-(benzo[d][1,3]dioxol-5-ylmethylene) pyrrolidin-2-one derivatives as potent anticonvulsant agents

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy

Outcomes Of Sustained-Release Formulation Of Valproate And Topiramate Monotherapy In Patients With Epilepsy: A Multi-Centre, Cohort Study

Hippocampal transcriptomic analyses reveal the potential antiapoptotic mechanism of a novel anticonvulsant agent Q808 on pentylenetetrazol-induced epilepsy in rats

Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity

LPM682000012, a Synthetic Neuroactive Steroid That Ameliorates Epileptic Seizures by Downregulating the Serpina3n/NF-κB Signaling Pathway

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

The Search for New Anticonvulsants in a Group of (2,5-Dioxopyrrolidin-1-yl)(phenyl)Acetamides with Hybrid Structure-Synthesis and In Vivo/In Vitro Studies

Synthesis, in silico screening, and biological evaluation of novel pyridine congeners as anti‐epileptic agents targeting AMPA (α‐amino‐3‐hydroxy‐5‐methylisoxazole) receptors

Electrophysiological and Pharmacological Characterization of a Novel and Potent Neuronal Kv7 Opener SCR2682 for Anti-Epilepsy

Discovery of New 3-(Benzo[b]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents—In Vitro and In Vivo Evaluation

Synthesis of 3,4-dihydroquinolin-2(1H)-one derivatives with anticonvulsant activity and their binding to the GABAA receptor

Hippocampus RNA Sequencing of Pentylenetetrazole-Kindled Rats and Upon Treatment of Novel Chemical Q808

Discovery of Novel Isonipecotic Acid-Based Heteroaryl Amino Acid Derivatives as Potential Anticonvulsant Agents: Design, Synthesis, In-Silico ADME Study, and Molecular Docking Studies

Electroresponsive Nanoparticles Improve Antiseizure Effect of Phenytoin in Generalized Tonic-Clonic Seizures

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates